Study Describing the Hypertensive Population Treated With Telmisartan and Conditions of Use by Medical Practitioners and Patients

Boehringer Ingelheim

Status: Completed

Conditions: Hypertension

Treatments: Drug: Telmisartan

Study type: Observational

Funder types: Industry

Identifiers

NCT02242851

502.450

Details and patient eligibility

About

Primary objective: to characterize hypertensive patients treated for at least 1 month with Telmisartan (alone or in combination with other drugs) in order to define the beneficiary population (those actually receiving the treatment).

Secondary objectives:

• to describe the patients' blood pressure values (when self-monitored) and satisfaction with the treatment (ease of use, efficacy, safety) on the basis of a patient self-questionnaire, filled out 4 weeks after consultation.
• to compare the characteristics of the beneficiary population to those of the initial target population defined in the SPC (summary of product characteristics) for Telmisartan

Enrollment: 5,018 patients

Sex: All

Ages: 21 to 94 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Hypertensive patients treated with Telmisartan for at least one month, consulting a medical practitioner (for whatever reason)

Exclusion Criteria:

Trial design

5,018 participants in 1 patient group

Hypertensive patients

Treatment:

Drug: Telmisartan